Greylin Investment Mangement Inc. increased its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 42.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,975 shares of the biotechnology company’s stock after buying an additional 885 shares during the period. Greylin Investment Mangement Inc.’s holdings in United Therapeutics Corporation were worth $386,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in UTHR. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of United Therapeutics Corporation by 11.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 717 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 73 shares during the period. Focused Wealth Management Inc boosted its position in shares of United Therapeutics Corporation by 17.5% in the first quarter. Focused Wealth Management Inc now owns 940 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 140 shares during the period. Advisory Services Network LLC bought a new position in shares of United Therapeutics Corporation during the first quarter valued at $147,000. Daiwa Securities Group Inc. boosted its position in shares of United Therapeutics Corporation by 17.4% in the first quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 200 shares during the period. Finally, Campbell & CO Investment Adviser LLC bought a new position in shares of United Therapeutics Corporation during the first quarter valued at $204,000.
United Therapeutics Corporation (NASDAQ UTHR) traded up 7.76% during trading on Friday, hitting $136.81. The stock had a trading volume of 2,166,309 shares. United Therapeutics Corporation has a 52-week low of $110.90 and a 52-week high of $169.89. The company has a 50-day moving average of $130.70 and a 200 day moving average of $136.25. The firm has a market cap of $5.94 billion, a P/E ratio of 15.87 and a beta of 1.51.
United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by $4.86. The company had revenue of $444.60 million during the quarter, compared to analysts’ expectations of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The company’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $4.42 EPS. On average, equities research analysts predict that United Therapeutics Corporation will post $14.47 earnings per share for the current fiscal year.
United Therapeutics Corporation announced that its board has authorized a stock buyback plan on Thursday, April 27th that authorizes the company to buyback $250.00 million in shares. This buyback authorization authorizes the biotechnology company to buy up to 4.6% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.
ILLEGAL ACTIVITY NOTICE: This article was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://stocknewstimes.com/2017/08/05/greylin-investment-mangement-inc-has-386000-stake-in-united-therapeutics-corporation-nasdaquthr-updated.html.
Several equities analysts have recently weighed in on the company. BidaskClub cut United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. ValuEngine cut United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Jefferies Group LLC reiterated a “sell” rating and issued a $105.00 price target on shares of United Therapeutics Corporation in a research report on Friday, July 14th. J P Morgan Chase & Co set a $125.00 price target on United Therapeutics Corporation and gave the company a “hold” rating in a research report on Tuesday, April 11th. Finally, UBS AG reiterated a “sell” rating and issued a $106.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. Six analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $134.50.
In other United Therapeutics Corporation news, Director Christopher Causey sold 590 shares of the firm’s stock in a transaction dated Thursday, July 6th. The shares were sold at an average price of $132.61, for a total value of $78,239.90. Following the completion of the sale, the director now owns 3,875 shares of the company’s stock, valued at $513,863.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 1,259 shares of the firm’s stock in a transaction dated Thursday, May 11th. The stock was sold at an average price of $122.00, for a total transaction of $153,598.00. Following the completion of the sale, the chief executive officer now directly owns 1,399 shares of the company’s stock, valued at approximately $170,678. The disclosure for this sale can be found here. In the last three months, insiders sold 23,758 shares of company stock valued at $3,058,699. 7.80% of the stock is owned by insiders.
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
